cyproterone and Atrophy

The influence of cyproterone acetate (CPA) containing drugs on the endometrium has not yet been investigated. Therefore, endometrial biopsies were obtained in 22 hirsute patients between day 14 and 28 of the cycle after 7-18 months of oral antiandrogen therapy. The effects of various regimens consisting of different doses of CPA in combination with ethinylestradiol (EE) were evaluated. The low-dose standard regimen (50 micrograms of EE plus 2 mg of CPA daily from day 5 to 25) caused regressive changes in the endometrium, i.e., sparse atrophic glands, relatively compact stroma, islands of stromal edema. These alterations correspond to those induced by conventional balanced low-dose combined oral contraceptives. High-dose reversed sequential regimen (40 micrograms of EE daily from day 5 to 25 plus 100 mg of CPA daily from day 5 to 14) resulted in pseudodeciduation and massive stromal edema. Pseudodeciduation during the early secretory phase is taken as a sign of the progestational depot effect of CPA, while the stromal edema is regarded as a result of the relatively unopposed estrogen intake during the second half of the treatment cycle. Thus, the effects of CPA containing drug on the endometrium depend essentially on their type, dosage and mode of administration.. The influence of cyproterone acetate (CPS) containing drugs on the endometrium has not yet been investigated. Therefore, endometrial biopsies were obtained in 22 hirsute patients between days 14-28 of the cycle after 7-18 months of antiandrogen oral therapy. The effects of various regimens consisting of different doses of CPA in combination with ethinyl estradiol (EE) were evaluated. The low dose standard regimen (50 mcg EE plus 2 mg CPA daily from days 5-25) caused regressive changes in the endometrium; i.e., sparse atrophic glands, relatively compact stroma, islands of stromal edema. These alterations correspond to those induced by conventional balanced low dose combined oral contraceptives. High dose reversed sequential regimen (40 mcg of EE daily from days 5-25 plus 100 mg CPA daily from days 5-14) resulted in pseudodeciduation and massive stromal edema. Pseudodeciduation during the early secretory phase is taken as a sign of the progestational depot effect of CPA, while the stromal edema is regarded as a result of the relatively unopposed estrogen intake during the 2nd 1/2 of the treatment cycle. Thus, the effects of a CPA containing drug on the endometrium depend essentially on their type, dosage, and mode of administration.

Topics: Adult; Atrophy; Biopsy; Cyproterone; Edema; Endometrium; Ethinyl Estradiol; Female; Hirsutism; Humans

Effects of cyproterone acetate, a synthetic steroidal compound, on the reproductive organs of female rats have been investigated. This agent caused reduction of ovarian weights indicative of suppression of pituitary gonadotrophins. Oestrogenic nature of cyproterone acetate was investigated in intact and ovariectomized rats taking uterine weight and vaginal keratinization as an index of oestrogenicity. Cyproterone acetate in ovariectomized animals induced vaginal keratinization and increased the uterine weights. These effects were parallel to the effect of oestradiol dipropionate in ovariectomized animals, thus indicating oestrogenic activity of cyproterone acetate. We may conclude that the above compound caused antifertility effects due to its oestrogenic nature at the dose level of 2 mg/alternate day in rats when the compound was administered subcutaneously.

Topics: Animals; Atrophy; Body Weight; Castration; Cyproterone; Estradiol; Female; Fertility; Genitalia, Female; Hyperplasia; Hypertrophy; Keratins; Organ Size; Ovary; Rats; Reproduction; Uterus; Vagina

Topics: Animals; Atrophy; Castration; Cyproterone; Dihydrotestosterone; Dominance-Subordination; Epididymis; Fertility; Male; Mice

Sixteen patients with prostatic carcinoma were treated with 200 mg of Cyproterone acetate daily. No other kind of hormonal treatment was given. Transrectal biopsies of the prostate were taken before the treatment was started, and at regular intervals afterwards. The treatment period lasted from 3 to 16 months, with an average of 9 months. A thorough examination of multiple sections from all specimens revealed no convincing signs of cellular involution. The study has demonstrated no specific or significant atrophic changes following Cyproterone acetate therapy. Some possible explanations regarding the effect of Cyproterone acetate on human malignant prostatic tissue are discussed.

Topics: Adenocarcinoma; Aged; Atrophy; Biopsy; Carcinoma; Cyproterone; Humans; Male; Middle Aged; Prostate; Prostatic Neoplasms

Topics: Animals; Atrophy; Cyproterone; Estradiol; Female; Fertility; Glycogen; Mice; Ovary; Proteins; RNA; Sialic Acids; Uterus

The effects of oral administration of 100 mg per kg per day cyproterone acetate (CPA) for four weeks on cells of the pars distalis, as revealed by the immunoperoxidase technique and chemical staining, were studied in the ovariectomized beagle bitch. For immunochemical staining antisera to the following hormones were used: canine GH, canine PRL, procine ACHT, bovine TSH beta, bovine LH beta and human FSH beta1. The most striking effects of the treatment were an overall increase in the relative proportion of GH cells and a marked morphological indication of high secretory activity in these cells. In contrast, PRL cells were not affected significantly. In all ovariectomized control bitches a marked atrophy of the cells stained for FSH beta (FSH cells) and hypertrophy of the cells shown to contain LH beta (LH cells) were observed. FSH cells became enlarged, while LH cells appeared reduced in size by administration of CPA. In some treated bitches ACTH/MSH cells showed atrophy and regressive changes, whereas TSH cells seemed to become enlarged and were more densely arranged. These structural responses indicate that, in addition to its partial antigonadotropic properties, CPA as a synthetic progesterone derivative may stimulate GH secretion and possibly suppress CRH-ACTH activity in the ovariectomized beagle bitch.

Topics: Adrenocorticotropic Hormone; Animals; Atrophy; Castration; Cyproterone; Dogs; Female; Follicle Stimulating Hormone; Growth Hormone; Humans; Hypertrophy; Immunoenzyme Techniques; Luteinizing Hormone; Pituitary Gland, Anterior; Prolactin; Swine; Thyrotropin

Pregnant ICR/JCL mice were treated with 6 mg of cyproterone acetate (CA) from days 14 to 20 of pregnancy to feminize male offspring. Feminized males delivered on day 20 of pregnancy by cesarean section were castrated the same day, injected with estradiol-17beta(E2) or sesame oil from the day of delivery (=day 1) to day 10 and sacrificed on day 60. In oil-injected feminized males, the vaginal epithelium was atrophic and did not show cornification. In feminized males given 20 microgram E2 neonatally, the vaginal epithelium exhibited well-differentiated stratified squamous organization, but was not cornified in seven out of the nine mice of this group. In the mice treated with 50 microgram E2, persistent cornification was recognized most frequently in the posterior two-thirds of the vaginal epithelium which is considered to originate from the urogenital sinus. However, the incidence of cornification in the anterior one-third which may contain the epithelial cells of müllerian duct was low. These results provide supporting evidence for the possible participation of epithelial cells which come from the urogenital sinus in the development of estrogen-independent persistent vaginal cornification in neonatally estrogenized mice.

Topics: Animals; Atrophy; Cell Differentiation; Cyproterone; Epithelium; Estrogens; Female; Male; Mice; Mullerian Ducts; Pregnancy; Time Factors; Vagina

Morphogenesis of the epididymis, which takes place in the chick, during the two months after hatching, is inhibited by the antiandrogenic drug, cyproteron acetate, which acts as strongly as castration. This fact is a good argument for our conception of sexual differentiation after which epididymis is induced by testosterone.

Topics: Animals; Atrophy; Chickens; Cyproterone; Epididymis; Male; Morphogenesis